# Docetaxel in Head and Neck Cancer

> **NCT00261703** · PHASE2,PHASE3 · COMPLETED · sponsor: **Sanofi** · enrollment: 439 (actual)

## Conditions studied

- Head and Neck Neoplasms

## Interventions

- **DRUG:** Docetaxel, Cisplatin, 5-fluorouracil (5-FU), radiotherapy
- **DRUG:** Cisplatin, 5-fluorouracil (5-FU), radiotherapy
- **OTHER:** Cisplatin + radiotherapy

## Key facts

- **NCT ID:** NCT00261703
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-12
- **Primary completion:** 2010-07
- **Final completion:** 2010-07
- **Target enrollment:** 439 (ACTUAL)
- **Last updated:** 2012-05-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00261703

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00261703, "Docetaxel in Head and Neck Cancer". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT00261703. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*